Structural Basis for the Dual Recognition of Helical Cytokines IL-34 and CSF-1 by CSF-1R  by Ma, Xiaolei et al.
Structure
ArticleStructural Basis for the Dual Recognition
of Helical Cytokines IL-34 and CSF-1 by CSF-1R
Xiaolei Ma,1 Wei Yu Lin,2 Yongmei Chen,3 Scott Stawicki,3 Kiran Mukhyala,4 Yan Wu,3 Flavius Martin,2
J. Fernando Bazan,1,5,6,* and Melissa A. Starovasnik1,*
1Department of Structural Biology
2Department of Immunology
3Department of Antibody Engineering
4Department of Bioinformatics
5Department of Early Discovery Biochemistry
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
6Present address: NeuroScience, Inc., 373 280th Street, Osceola, WI 54020, USA
*Correspondence: jfbazan@gmail.com (J.F.B.), starovasnik.melissa@gene.com (M.A.S.)
DOI 10.1016/j.str.2012.02.010SUMMARY
Lacking any discernible sequence similarity, inter-
leukin-34 (IL-34) and colony stimulating factor 1
(CSF-1) signal through a common receptor CSF-1R
on cells of mononuclear phagocyte lineage. Here,
the crystal structure of dimeric IL-34 reveals a helical
cytokine fold homologous to CSF-1, and we further
show that the complex architecture of IL-34 bound
to the N-terminal immunoglobulin domains of
CSF-1R is similar to the CSF-1/CSF-1R assembly.
However, unique conformational adaptations in the
receptor domain geometry and intermolecular inter-
face explain the cross-reactivity of CSF-1R for two
such distantly related ligands. The docking adapta-
tions of the IL-34 and CSF-1 quaternary complexes,
when compared to the stem cell factor assembly,
draw a common evolutionary theme for transmem-
brane signaling. In addition, the structure of IL-34
engaged by a Fab fragment reveals the mechanism
of a neutralizing antibody that can help deconvolute
IL-34 from CSF-1 biology, with implications for ther-
apeutic intervention in diseases with myeloid patho-
genic mechanisms.
INTRODUCTION
Interleukin-34 (IL-34) was recently identified as the second func-
tional ligand for colony stimulating factor (CSF)-1R (also known
as cFMS) in a human monocyte proliferation screening assay
(Lin et al., 2008). This discovery has long been foreshadowed
by the more severe phenotype observed in CSF-1R null mice
in comparison to that of CSF-1-deficient CSF-1op/CSF-1op
mice (Dai et al., 2002). Like CSF-1 (also known as M-CSF), the
better characterized ligand for CSF-1R, IL-34 stimulates phos-
phorylation of ERK1/2 in human monocytes and promotes the
formation of the granulocyte-macrophage progenitor andmega-
karyocyte progenitor in human bone marrow cultures (Lin et al.,
2008). Mediated by the common receptor CSF-1R, IL-34 and
CSF-1 serve as the key regulators of the differentiation, prolifer-676 Structure 20, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rightsation, and survival of the mononuclear phagocyte lineage cells
such as monocytes, macrophages, and osteoclasts (Droin and
Solary, 2010).
The function of IL-34 bears strong resemblance to that of
CSF-1, but with several notable differences. Both cytokines
support cell growth and survival in cell culture studies equiva-
lently (Chihara et al., 2010; Wei et al., 2010). The IL-34 gene,
when expressed under the control of the CSF-1 promoter, could
rescue the phenotype of CSF-1op/CSF-1op mice (Wei et al.,
2010). IL-34 can also substitute for CSF-1 to support RANKL-
induced osteoclastogenesis (Baud’huin et al., 2010). However,
IL-34 has been shown to induce a stronger but transient activa-
tion of CSF-1R and downstream effectors and rapidly downre-
gulates CSF-1R expression (Chihara et al., 2010). Moreover,
IL-34 and CSF-1 exhibit different spatiotemporal patterns of
expression in both embryonic and adult tissues, which lead to
complementary activation of CSF-1R (Wei et al., 2010). Most
strikingly, IL-34 but not CSF-1 mRNA is detected together with
CSF-1R in embryonic brain, which could explain why microglia
develop in CSF-1-deficient but not CSF-1R-deficient mice
(Ginhoux et al., 2010; Mizuno et al., 2011). Thus, while IL-34
and CSF-1 resemble each other, they are not necessarily iden-
tical in their developmental roles, biological activity, and signal
activation kinetics or strength.
Despite a lack of appreciable sequence similarity with other
proteins, IL-34 was proposed by fold recognition to be a short-
chain helical cytokine belonging to the same family as CSF-1,
stem cell factor (SCF), and Flt3L (J.F.B., unpublished data;
Garceau et al., 2010). These latter three dimeric hematopoietic
cytokines functionally mimic the PDGF and VEGF cystine knot
dimers, which are the activating ligands of the PDGFR subfamily
of receptor tyrosine kinases (RTKs) (Savvides et al., 2000;
Wiesmann and de Vos, 2000). All members of this RTK family
share a similar overall architecture comprising multiple extracel-
lular immunoglobulin (Ig)-like domains, a single transmembrane
segment, and a cytoplasmic tyrosine kinase domain. Upon
stimulation, CSF-1R dimerizes and autophosphorylates certain
tyrosine residues in its intracellular domain, which recruits
SH2-containing effector proteins and modulates macrophage
differentiation (Pixley and Stanley, 2004).
The structure of dimeric CSF-1 in complex with the first three
Ig domains of CSF-1R reveals a nonsymmetrical 2:1 complex, inreserved
Figure 1. Structure of the hIL-34 Functional
Core
(A) Schematic representation of hIL-34. A pre-
dicted N-linked glycosylation site is indicated with
an asterisk. The disulfide bridges are shown as
dashed lines.
(B) hIL-34s is active in promoting human mono-
cyte viability. Error bars indicate standard devia-
tion of triplicate samples.
(C) Ribbon representation of the dimeric hIL-34s
structure.
(D) Ribbon representation of the mCSF-1 dimer
structure.
(E) Superposition of hIL-34s and mCSF-1 struc-
tures based on optimal backbone alignment of
their corresponding monomer structures, in two
views related by a rotation of 90.
See also Figure S1.
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Structures of Human IL-34 and IL-34/CSF-1R Complexwhich one CSF-1 protomer approaches its receptor at the cleft
between D2 and D3, while the second CSF-1 protomer remains
unoccupied (Chen et al., 2008). This monovalent binding mode
was recently reconciled as an assembly intermediate by a low
resolution electron microscopy envelope of the complete
CSF-1 ligand-receptor complex, which captured the anticipated
bivalent assembly (Elegheert et al., 2011). In comparison to the
extensively investigated CSF-1/CSF-1R molecular interaction,
the structural basis whereby CSF-1R is also able to recognize
IL-34, a distantly-related ligand with scant sequence identity,
has remained elusive. IL-34 can function independently but
does not synergize with CSF-1 (Lin et al., 2008). Indeed, CSF-1
competes with IL-34 for binding to CSF-1R (Wei et al., 2010),
suggesting a common ligand-binding site on CSF-1R. In
contrast, a recent bioinformatics analysis centered on the junc-
tion between D3 and D4 of CSF-1R as strongly conserved during
evolution and suggested a unique binding mode distinct from
that used by the CSF-1/CSF-1R complex (Garceau et al., 2010).Structure 20, 676–687, April 4, 2012Herein, we present crystal structures of
IL-34 alone and in complex with CSF-1R
and characterize their binding properties
in solution. We show that IL-34 indeed
belongs to the short-chain helical cyto-
kine family, with the smallest dimerization
interface among the family members. The
structure of the IL-34/CSF-1R complex
shows a similar overall ligand/receptor
assembly in terms of the domains
involved, as was seen for the CSF-1
complex. However, the receptor domains
undergo an unexpected rearrangement,
resulting in different interface composi-
tions. A careful comparison between
these two cytokine signaling complexes
provides an understanding of the molec-
ular determinants that allow CSF-1R
to bind two structurally related yet
evolutionarily distant ligands, IL-34 and
CSF-1. Furthermore, co-crystal struc-
tures of IL-34 in complex with Fab frag-ments of two IL-34 antibodies provide structural rationales for
their respective nonblocking and neutralizing activities and offer
novel insights into therapeutic development.
RESULTS
Structure of the Active Core of Human IL-34
The mature full-length human IL-34 (hIL-34fl) comprises 222
amino acids, but its last50 residues are predicted to be largely
disordered by PsiPRED (McGuffin et al., 2000). Moreover,
constructs of hIL-34 containing the first 202 or 182 residues
are indistinguishable from the full-length protein in activating
the growth of TF-1-fms cells, while a construct encompassing
only the first 162 residues shows significantly diminished activity
(Chihara et al., 2010). In addition, six of seven (all but C199)
cysteines found in the hIL-34 gene are well conserved across
species (Figure 1A; Figure S1E available online). Therefore, a
truncated IL-34 construct hIL-34s comprising residuesª2012 Elsevier Ltd All rights reserved 677
Table 1. X-Ray Data Collection, Phasing, and Refinement Statistics
Data Collection Variable hIL-34s hIL-34s/hCSF-1R hIL-34s/FAb1.1 hIL-34s/FAb2
PDB ID 4DKC 4DKD 4DKE 4DKF
Wavelength (A˚) P21 P3121 P212121 C2
Space group a = 57.69 A˚ a = b = 101.4 A˚ a = 105.5 A˚ a = 117.9 A˚
Cell dimension b = 77.87 A˚ c = 175.3 A˚ b = 122.5 A˚ b = 181.8 A˚
c = 58.08 A˚ a = b = 90 c = 149.2 A˚ c = 79.25 A˚
a = g = 90 g = 120 a = b = g = 90 a = g = 90
b = 103.2 b = 118.3
Resolution (A˚) 50.0-1.85 (1.92-1.85) 50.0-3.0 (3.11-3.00) 50.0-3.0 (3.11-3.00) 50.0-2.6 (2.69-2.60)
Total observations 154,925 164,357 208,888 243,871
Unique observations 42,509 21,502 38,972 44,009
I/SigI 11.3 (2.0) 23.5 (2.8) 16.7 (2.2) 11.0 (2.3)
Redundancy 3.6 (3.2) 7.6 (7.0) 5.4 (5.0) 5.5 (5.4)
Completeness (%) 99.8 (99.0) 99.8 (99.8) 99.6 (99.9) 99.3 (96.9)
Rsym
a (%) 9.3 (51.9) 6.1 (62.7) 8.6 (62.3) 11.1 (60.9)
Refinement
Resolution (A˚) 50.0-1.85 50.0-3.0 50.0-3.0 50.0-2.6
No. of protein atoms 2,614 4,724 8,948 8,729
No. of sugar atoms 78 134 111 122
No of waters 486 16 50 126
Rwork 17.4% 25.2% 23.1% 22.5%
Rfree
b 20.3% 28.7% 26.5% 25.6%
rmsd bond lengths (A˚) 0.015 0.004 0.009 0.009
rmsd bond angles () 1.4 1.0 0.9 1.0
Ramachandran plot
Most favored (%) 93.9 86.9 90.5 89.7
Additional allowed (%) 6.1 11.8 8.9 9.8
Generously allowed (%) 0.0 0.4 0.6 0.1
Disallowed (%) 0.0 0.9 0.0 0.4
Values in parentheses represent the highest resolution shell.





i jIi(hkl)  hI(hkl)ij/PhklPiIi(hkl), where the summations are over i observations of each reflections and all hkl. hI(hkl)i is the average
intensity of the i observations. Rwork = jF(obs)  F(calc)j/F(obs).
bRfree is calculated for 5% of randomly selected reflections not used in the refinement.
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Structures of Human IL-34 and IL-34/CSF-1R ComplexN21–V193 of the mature polypeptide was used for all subse-
quent studies, unless otherwise noted. hIL-34s is as active as
CSF-1 and slightly more active than recombinant hIL-34fl in its
ability to promote human monocyte viability (Figure 1B).
The structure of the active core of hIL-34 was determined by
molecular replacement (MR) from its complexwith a nonblocking
antibody Ab2 Fab fragment (FAb2) at 2.6 A˚ resolution and refined
using a 1.85 A˚ resolution data set collected from a single hIL-34s
crystal (Table 1). hIL-34s has the distinctive antiparallel four-helix
bundle cytokine fold consisting of aA, aB, aC, and aD (Sprang
and Bazan, 1993), but the structure contains a number of notable
features outside this core portion (Figure 1C). The crossing
b strands 1 and 2 are much shortened and partially substituted
by three short helices (a1, a2, and a3) compared to CSF-1
(Chen et al., 2008; Pandit et al., 1992) (Figure 1D). Furthermore,
two intramolecular disulfide pairs located at the pole of each pro-
tomer share no structural similarities with disulfide bonds found
in the structures of the related dimeric short-chain helical cyto-678 Structure 20, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rightskines CSF-1, SCF, and Flt3L (Jiang et al., 2000; Savvides
et al., 2000; Zhang et al., 2000). The first disulfide bond (C35-
C180) connects helices aA and aD, while the second disulfide
bond (C177-C191) connects aD to the C-terminal helix a4 (Fig-
ure S1D). Consequently, the C-terminal tail including a4 is in-
verted, compared with that of CSF-1, and packs on to the
surface of aA and aD (Figure 1E). The other two cysteines,
C168 and C179, remain unpaired and consequently are not
essential for the proper folding of hIL-34s. Overall, as judged
by PDBeFOLD structural superposition (Krissinel and Henrick,
2004), hIL-34s is structurally most similar to SCF (root-mean-
square deviation (rmsd), 2.6 A˚) yet more divergent from the func-
tionally related CSF-1 (rmsd, 3.2 A˚; Figures S1A, S1B, and S1C).
The two protomers of hIL-34s in the asymmetric unit further
assemble into a noncovalent dimer in a manner similar to that
seen for CSF-1, SCF, and Flt3L. In forming the IL-34 dimer,
each subunit buries 656 A˚2, with the aA-b1 loop and aB-aC
loop from one monomer interlocking with the reciprocalreserved
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Structures of Human IL-34 and IL-34/CSF-1R Complexsegments of the other monomer. A compact and relatively flat
hydrophobic patch centering on P59/P590 is formed by packing
the side chains of H56, Y57, F58, P59, and Y62 of one protomer
against residues P1140, H1130, L1100, L1090, V1080, Y620, P590,
and F580 from the neighboring monomer. These interactions
may confer obligate IL-34 dimer formation despite the smaller
buried surface area (1,310 A˚2) compared with the related nonco-
valent SCF and Flt3L dimerization interfaces, comprising
1,690 A˚2 and 1,640 A˚2, respectively. The residues at the IL-34
dimer interface are highly conserved among orthologs from
other species (Figure S1E). The dimeric organization observed
in hIL-34s crystals is likely to be representative of the organiza-
tion of IL-34 in solution as the same ‘‘head-to-head’’ dimeric
arrangement is also present in the three IL-34 complex struc-
tures discussed in this article.
Biophysical Characterization of the IL-34/CSF-1R
Complex
To probe the oligomeric state of hIL-34s in solution, we used
analytical size exclusion chromatography (SEC) (Figure 2A).
The theoretical molecular mass of the hIL-34s monomer is
22 kDa, yet the protein elutes earlier than the 44 kDa reference,
indicating that hIL-34s forms dimers in solution, in agreement
with the twofold noncrystallographic symmetric dimer structure
observed in the hIL-34s crystal. For our assessment of the
molecular size of IL-34 ligand/receptor complexes, a construct
containing nearly the entire extracellular domain including
Ig-like domains D1 through D5 of the receptor (hCSF-1RD1-D5)
was mixed with IL-34 at 1:1 protomer molar ratios and was
analyzed with the same technique. The apparent size of this
complex is consistent with the size calculated for a 2:2 complex
(Figure 2A). Similarly, to narrow down the minimal receptor
construct necessary for complex formation, a mixture of hIL-
34s with a receptor construct containing only the first three
Ig-like domains (hCSF-1RD1–D3) was subject to SEC analysis,
revealing an apparent size that is larger than 158 kDa, in agree-
ment with a 2:2 complex (Figure 2A).
To accurately determine the stoichiometry and energetics of
hIL-34 binding to hCSF-1R and compare them with hCSF-1
binding, we assessed the thermodynamic parameters for
binding by isothermal titration calorimetry (ITC) (Figures 2B and
2D). Titrating hCSF-1R into hIL-34s confirmed that both the
full-length and truncated forms of the receptor are saturated
by equal molar amounts of IL-34 monomer. This, in conjunction
with the apparent sizes determined by analytical SEC, strongly
supports a 2:2 cytokine/receptor stoichiometry in solution
for the complex (Figure 2D). Note that the high affinity of the
hIL-34s/hCSF-1RD1-D5 interaction yields a steep titration transi-
tion that precludes determining the dissociation constant with
high accuracy (Figure 2B, left). Consequently, we carried out
displacement ITC by titrating hCSF-1RD1-D5 into a mixture of
hIL-34 with hCSF-1RD1–D3 (Figure 2B, right). The binding
isotherms determined herein indicate that IL-34 binding to its
receptor is driven mainly by enthalpic terms. The exothermic
nature of IL-34 binding to both CSF-1RD1–D3 and CSF-1RD1-D5
indicates that IL-34/CSF-1R complex formation likely involves
key polar interactions. Inclusion of the membrane-proximal
domains CSF-1RD4-D5 leads to a large increase in its affinity for
IL-34 (1.6 and 94 nM Kd for CSF-1RD1-D5 and CSF-1RD1–D3,Structure 20respectively). Compared to CSF-1RD1–D3, CSF-1RD1-D5 is signif-
icantly more favorable enthalpically, although slightly disfavored
entropically. These results suggest that, although CSF-1RD1–D3
is sufficient to confer high-affinity ligand-binding, CSF-1RD4-D5
likely contains additional homotypic receptor interaction sites
on formation of the entire cytokine/receptor signaling complex,
as seen in the complex structure of SCF bound to the full ecto-
domains of a KIT receptor dimer (Yuzawa et al., 2007). The better
characterized ligand CSF-1, however, exhibits 9.5 and 13-fold
lower affinity compared to IL-34 for binding to hCSF-1RD1–D3
and hCSF-1RD1-D5, respectively (Figures 2C and 2D). Compared
to IL-34, CSF-1 complexes are driven by both favorable enthalpy
and entropy. Similar to IL-34, the human CSF-1 titrations also
suggest 2:2 ligand/receptor stoichiometries for both forms of
the receptors. The bivalent binding of hCSF-1 to hCSF-1R D1–
D3 is consistent with the most recent human/murine CSF-1/
CSF-1R comparative studies (Elegheert et al., 2011) and
contrasts with an earlier report that suggested monovalent
binding of mCSF-1 to mCSF-1RD1–D3 in solution. (Chen et al.,
2008).
To further understand the kinetics of cytokine/receptor
binding in this system, we immobilized biotinylated IL-34 or
CSF-1 on streptavidin-coated biosensor tips to measure rates
of association and dissociation with serial receptor dilutions
using the Bio-Layer Interferometry (BLI) technique (Figure S2).
The results from this orthogonal method also confirm that
IL-34 (kon = 2.9 3 10
5 s-1M-1, koff = 3.5 3 10
2 s-1, Kd =
120 nM) binds CSF-1RD1–D3 more tightly than CSF-1 (kon =
7.7 3 104 s-1M-1, koff = 5.4 3 10
2 s-1, Kd = 720 nM), primarily
because of a 3.8-fold faster kon coupled to a slightly slower koff.
Structure of the IL-34/CSF-1RD1–D3 Complex
The 3.0 A˚ resolution structure of hIL-34s bound to hCSF-1RD1–D3
was solved by MR using structures of hIL-34s and mCSF-
1RD1–D3 (Chen et al., 2008) (PDB 3EJJ) as search probes
(Table 1). Although all biophysical methods tested indicate
hCSF-1RD1–D3 forms a 2:2 complex with hIL-34s in solution,
the crystal structure unambiguously revealed one hCSF-1RD1–D3
bound to one hIL-34s homodimer in the asymmetric unit. The
analogous receptor-binding site on the adjacent protomer is
involved in crystal packing, prohibiting formation of the expected
2:2 complex in this crystal form (Figure S3). Nevertheless, this
structure nicely reveals the IL-34/receptor interface. IL-34 is
bound to a concave surface formed by D2 and D3 of CSF-1R
in a configuration resembling that used by CSF-1 when bound
to the CSF-1R (Figures 3A and 3B). A similar two-site binding
mode seen in the CSF-1/receptor complex is also preserved in
the IL-34/CSF-1R interface, with Site 1 involving interactions
between IL-34 and domain D2 of the receptor, and Site 2
involving interactions between IL-34 and receptor domain D3.
Each site provides 1,280 A˚2 and 1,160 A˚2 total buried surface
area, respectively (Figure 3B). The linker between D2 and D3,
although fully ordered in the structure, is spared from the interac-
tion with IL-34, which effectively parses the IL-34/CSF-1R inter-
face into two spatially separated sites.
Site 1 is formed mainly by receptor D2 domain residues
comprising the CD and EF loops that dock on to the rugged
surface provided by IL-34 helices aB, aC, the intervening loop,
and a3 (Figure 4A). Complementary electrostatic interactions, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 679
Structure
Structures of Human IL-34 and IL-34/CSF-1R Complex
680 Structure 20, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rights reserved
Structure
Structures of Human IL-34 and IL-34/CSF-1R Complexbetween the negatively charged surface of IL-34 and the posi-
tively charged surface onCSF-1R in this region appear important
in mediating IL-34 binding at this site (Figure 3C). In particular,
centrally located salt bridges are formed between the basic resi-
dues R142 and R146 of CSF-1R and the acidic E103 on IL-34.
R144 and R150 of CSF-1R at the periphery of the CD loop
engage in hydrogen-bonding interactions with the side chain
oxygen of N150 and the backbone carbonyl oxygen of Q106
and L109, respectively. A small hydrophobic patch formed by
the aliphatic side chain of L127 in IL-34 fits snugly between
F169 and I170 of CSF-1R. While this site appears dominated
by polar interactions, a number of intermolecular van der Waals
contacts also line the interface as detailed in Table S1.
The slightly smaller Site 2 is formedmainly by receptor D3 resi-
dues from the BC andDE loops and strandD, packed against the
surface generated by portions of IL-34 helices aA, aC, and a4
(Figure 4C). This interface can be further divided into two polar
interaction regions, separated by a hydrophobic area formed
by IL-34 residues F40 and L125 and CSF-1R residues V231,
Y257, and F252. The first region is formed by a combination of
backbone and side chain hydrogen-bonding interactions
between the beginning of the CSF-1RD3 D-strand and IL-34
a4. The side chain amide hydrogen and oxygen of N187 of
IL-34 participates in up to three hydrogen bonds with the
receptor involving the side chain amide of Q249 and the back-
bone nitrogen and carbonyl oxygen of S248 of CSF-1R. Addi-
tionally, two backbone-backbone hydrogen bonds are formed
between CSF-1R Q248 and IL-34 S184 and L186. Deletion of
residues constituting the a4 region in IL-34 results in drastic
reduction in protein expression levels and significantly weaker
activity in terms of the ability to stimulate the growth of TF-1-
fms cells (Chihara et al., 2010). The results reported here confirm
that residues encompassing a4 are an integral part of the active
core domain of IL-34 and are therefore important for its activity.
The second polar region in Site 2 encompasses three side-
chain-mediated hydrogen bonds between the terminal side
chain atoms of IL-34 N128, K44 and E121, and the hydroxyl
group of Y257, the carbonyl oxygen of F252, and the backbone
amide of N254 of CSF-1R. Additional interactions mediated by
van der Waals contacts are listed in Table S1.
Structural Basis for IL-34 Neutralization by a Blocking
Antibody Ab1.1
To dissect the discrete functions of IL-34 and CSF-1 and explore
the therapeutic benefit from blocking IL-34 signaling, we used
phage display to raise antibodies that specifically antagonize
both human and murine IL-34, enabling the interrogation of
IL-34 function in both human patients and rodent models. Ab1Figure 2. Biophysical Characterization of hIL-34s and hCSF-1 Interact
(A) Analytical SEC analyses of hIL-34s, CSF-1RD1–D3, and CSF-1RD1-D5 and the
pendent runs as described in the Experimental Procedures and referenced to m
fractions shown on the right.
(B) ITC measurements of the binding of CSF-1RD1-D5 to hIL-34s (left), CSF-1RD1–D
1RD1-D5 (right).
(C) ITC measurements of the binding of CSF-1RD1-D5 to hCSF-1 (left) and CSF-1
(D) Summary of the proteins in the syringe and their concentrations, the proteins
(DS), Gibbs free energy change (DG), binding affinity (Kd), and stoichiometry (n)
indicates not determinable.
See also Figure S2.
Structure 20was identified by screening VH and VH/VL phage display libraries
and selected out of a panel of 96 clones for its IL-34 high binding
affinity and blocking activity. Ab1 was subsequently affinity-
matured using a soft randomization strategy as described in the
Supplemental Experimental Procedures. When reformatted as
full-length IgG molecules, Ab1.1 shows a 140-fold improvement
in binding affinity (Kd = 120 pM), asmeasured byBLI experiments
when compared with the parental clone (Kd = 17 nM, Table S2),
due to five and four amino acid changes in the sequences
of CDR-L2 and H2, respectively. In human monocyte viability
(Figure 5A) and proliferation (Figure S4) assays, the biological
activity of IL-34 is effectively blocked by this antibody, similar to
the receptor Fc fusion, but not by an anti-CSF-1 antibody.
To better understand the mechanism whereby Ab1.1 blocks
IL-34 biological activity, we solved the structure of hIL-34s in
complex with the Fab fragment of Ab1.1 (FAb1.1) at 3.0 A˚ reso-
lution (Table 1). Crystals contained one hIL-34s dimer bound to
two FAb1.1 s in the asymmetric unit. It is interesting that each
FAb1.1 recognizes a largely continuous area at the junction of
two IL-34 protomers (Figure 5B). Four salt bridges (R50FAb1.1-
E111IL-34, R100bFAb1.1-E111IL-34, R100bFAb1.1-D107IL-34, and
K100aFAb1.1-E103IL-34) form an ‘‘electrostatic zipper’’ along the
groove between aB and aCof IL-34 (Figure 5C). This strong elec-
trostatic complementarity between IL-34 and FAb1.1 is reminis-
cent of the Site 1 charge-charge interactions in the IL-34/CSF-1R
complex described earlier (Figure 5D). The details of additional
antibody-antigen contacts are provided in Table S3. Superposi-
tion of IL-34 in the IL-34/Ab1.1 and IL-34/CSF-1R complexes
shows that both the heavy and light chains of the antibody clash
with CSF-1R (Figure 5B). FAb1.1 binds to an epitope that
overlaps largely with binding epitopes responsible for CSF-
1RD2 binding at Site 1. Therefore, the binding of Ab1.1 to IL-34
would compete directly for association on CSF-1R, explaining
the molecular mechanism of IL-34 signaling blockade.
DISCUSSION
Conformational Change in IL-34 upon Binding
to the Receptor
Herein, we report three-dimensional structures of IL-34, solved
both on its own and in complex with CSF-1R. Comparison of
the IL-34 protomer structure in its unbound and CSF-1R-bound
forms reveals that the structure of the cytokine is nearly
unchanged upon binding to its receptor. Even the side chain
rotamers adopted by the receptor interfacial residues show little
difference between the free and bound states, indicating that
the unbound IL-34 promoter is highly compatible with and
primed for receptor binding. The apparent rigidity of the IL-34ions with hCSF-1R Ectodomain Fragments
ir corresponding complexes. Chromatograms are shown overlaid from inde-
olecular weight standards. Inset: SDS-PAGE of samples derived from peak
3 to hIL-34s (middle), and displacement of CSF-1RD1–D3 from hIL-34s by CSF-
RD1–D3 to hCSF-1 (right).
in the cell and their concentrations, the enthalpy change (DH), entropy change
derived from analyses of the five ITC experiments shown in (B) and (C). N.D.
, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 681
Figure 3. Structure of the IL-34/CSF-1RD1–D3 Complex
(A and B) Frontal and side views of the IL-34/CSF-1RD1–D3 complex shown as
ribbon representation with the two IL-34 protomers in pale blue and dark blue,
and the CSF-1R D1, D2, and D3 domains in pale yellow, bright orange, and
olive, respectively. The disulfide bonds are shown in stickmodel, in yellow, and
the N-linked glycans are depicted as ball and stick model. The cytokine-
receptor interaction Sites 1 and 2 are circled.
(C) Complementarity in electrostatic potential in the IL-34/CSF-1RD1–D3
interface. Left panel depicts the electrostatic potential mapped on to the
molecular surface of CSF-1RD1–D3 with a semitransparent cartoon diagram of
bound IL-34 that is shown in white. Right panel depicts the electrostatic
surface potential of IL-34 with CSF-1RD1–D3 shown in semitransparent ribbon
diagram shown in white.
See also Figure S3 and Table S1.
Figure 4. Comparison of the Site 1 and 2 Interfaces for CSF-1R in
Complex with IL-34 and CSF-1
(A–D) Close-up views of Site 1 and Site 2 of the IL-34/CSF-1R (A and C) or
CSF-1/CSF-1R (B and D; PDB 3EJJ) interfaces. IL-34 and CSF-1 are shown in
light blue and pale green, respectively; the D2 and D3 of CSF-1R are shown in
bright orange and olive, respectively. Key cytokine receptor interacting resi-
dues are shown as sticks, hydrogen bonds are shown as dashed red lines, and
secondary structure elements are marked on the ribbons and strands. The key
residues shared by both cytokines are shown in magenta. IL-34/CSF-1
specific contacts are labeled in blue and green.
(E–F) Shared and distinct contacts on the CSF-1R surface in IL-34/CSF-1R
complex (E) and CSF-1/CSF-1R complex (F). Surface representation of
CSF-1R with residues interacting with IL-34 (light blue), CSF-1 (pale green), or
both receptors (light pink) are highlighted.
See also Figure S6.
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Structures of Human IL-34 and IL-34/CSF-1R Complexprotomer structure based on comparisons of the four structures
presented here is consistent with the recently determined Flt3L
structure (Verstraete et al., 2011) but quite different from the
more plastic CSF-1 (Chen et al., 2008) or SCF (Liu et al., 2007;
Yuzawa et al., 2007) structures, which must undergo local struc-
tural rearrangements to accommodate receptor binding. Never-
theless, we observe significant changes in the orientation of one
IL-34 protomer relative to the other protomer about the dimer
interface upon complex formation (Figure S5). When described
by the tilt angle of aC, receptor binding or FAb1.1 binding
induces a 6.6 or 4.6 increase in the angles between IL-34 pro-
tomers, respectively. Similar hinge-like rigid body movements
were reported previously in the CSF-1/CSF-1R, SCF/KIT, and
Flt3L/Flt3 systems. Unexpectedly, FAb2 triggers a similar rota-
tion but along the reverse direction, resulting in 6.4 decrease
in the tilt angle (Figure S5; Table S4). Such high degree of struc-
tural plasticity is unprecedented in other dimeric four-helix
bundle cytokines and can likely be attributed to the smaller,
and very hydrophobic, IL-34 dimerization interface.682 Structure 20, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rightsThe Dual Recognition of IL-34 and CSF-1 by CSF-1R
While IL-34 and CSF-1 are sparsely similar at the primary
sequence level, they indeed adopt a similar four-helical bundle
core fold and related dimerization and receptor-bindingreserved
Figure 5. Structural Basis for the Blockage of IL-34
Signaling by Ab1.1
(A) Inhibition of IL-34 biological activity by Ab1.1 in the
monocyte viability assay. Error bars indicate standard
deviation of triplicate samples.
(B) Overlay of the hIL-34/FAb1.1 complex on to the hIL-34/
CSF-1RD1–D3 complex based on the superposition of one
hIL-34 protomer. The hIL-34s is shown with cartoon
representation in blue with semitransparent surface.
FAb1.1 is shown in teal (heavy chain) and light cyan (light
chain). CSF-1RD1–D3 is rendered with a ribbon model with
D1, D2, and D3 in light yellow, bright orange, and olive,
respectively.
(C) A close-up view of the interactions of the CDR-loops
(H1–H3, L3) of FAb1.1 with hIL-34s (cartoon representa-
tion). Critical residues involved in the interface interactions
are highlighted in stick models.
(D) Electrostatic surface potential of FAb1.1 with a semi-
transparent cartoon diagram of bound IL-34 that is shown
in white.
See also Figures S4, S5, and S7 and Tables S2 and S3.
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Structures of Human IL-34 and IL-34/CSF-1R Complexinterfaces, with differences apportioning to extra-core loops and
structural embellishments—a recurrent finding in the compar-
ison of helical cytokine structures (Bazan, 1991b; Hill et al.,
2002; Rozwarski et al., 1994). In fact, a telling remnant of helical
cytokine ancestry (aside from the three-dimensional fold rela-
tionship) is the similarity in exon/intron structures of their respec-
tive genes (Bazan, 1991a; Betts et al., 2001); in this respect, the
structure of the IL-34 gene is homologous to the CSF-1, SCF,
and Flt3L genes (Figure S1D).
Both IL-34 and CSF-1 bind the CSF-1R receptor with high
affinity and induce similar, if not identical, biological activity
(Chihara et al., 2010; Lin et al., 2008). This striking phenomenon
prompted us to directly compare this structure of human IL-34/
CSF-1R complex to that of the murine CSF-1/CSF-1R complex
to determine the molecular mechanisms governing receptor
sharing by these structurally similar but evolutionally divergent
ligands. Overall, CSF-1R utilizes a common ‘‘dual interface
mode’’ for its interactions with both cytokines. The total
solvent-accessible surface area buried at the interface between
IL-34 and CSF-1R is approximately 2,400 A˚2, significantly larger
than the 1,700 A˚2 buried in the CSF-1/CSF-1R interface (Figures
4E and 4F). Notably, the regions of CSF-1R that interact with
IL-34 and CSF-1 largely overlap yet are not identical. Further
analysis reveals substantial differences in both the numbers
and types of interactions between the two CSF-1R signaling
complexes. The aligned sequences of human and mouse CSF-
1R are greater than 70% identical, with no sequence gaps
throughout the D1–D3 region. This close correspondence facili-
tates the structural comparison of the interfaces of closely
related human and mouse CSF-1R chains in their respective
complexes with human IL-34 complex and mouse CSF-1Structure 20, 676–687, April 4(Chen et al., 2008). The Site 1 interfaces share
a number of common features. Most of the polar
interactions between the CSF-1R CD loop and
helix aB of both cytokines are mediated by the
same group of basic residues on the receptor
(R142, R146, and R150), which dictate the
shared charge complementarity in this region(Figures 4A and 4B). In particular, these three residues on
CSF-1R remain invariant while other shared interfacial contacts
are more divergent among CSF-1R orthologs in other eukaryotic
species (Figure S6C). A centrally located acidic residue (E103
in IL-34 and D59 in CSF-1) at the second turn of helix aB
participates in salt bridges in both structures. The hydrogen-
bonding interactions between the EF loop of CSF-1R and N85
in CSF-1 are substituted by a nearby hydrophobic patch in
the IL-34/CSF-1R complex. The most prominent differences
are located at the edges of the CD and EF loops of CSF-1R.
The salt bridges at the lower edge of the two connecting loops
between K151CSF-1R, K168CSF-1R, and E78CSF-1 are absent in
IL-34/CSF-1R. Instead, a unique hydrogen bond bridging
N150IL-34 and R144CSF-1R bring IL-34 into close contact with
the upper edge of the CD loop. The differences between the
Site 2 interfaces are even more striking (Figures 4C and 4D).
Wherein an extensive hydrogen-bonding network between the
CD loop, D strand and DE loops of CSF-1R, and helices aA,
aC, and a4 in IL-34 forms the core of the interface at Site 2;
however, such interactions are completely absent in the CSF-
1/CSF-1R complex, resulting in a much smaller Site 2 interface.
However, hydrophobic interactions involving V231 on the
receptor are observed in both complexes.
Large Rearrangement in the CSF-1R Receptor D2-D3
Domain Orientation in the IL-34 versus CSF-1
Cytokine/Receptor Complexes
The orientation of receptor domains D1 and D2 are conserved in
both cytokine/receptor complexes; however, the orientation of
receptor domain D3 relative to D1-D2 shows a 27 change
when comparing the two complexes (Figure 6A). Engagement, 2012 ª2012 Elsevier Ltd All rights reserved 683
Figure 6. Large Reconfiguration of the CSF-1RD2–D3 Elbow upon
IL-34/CSF-1 Binding
(A) Superimposition of D1-D2 domains from the hIL-34/CSF-1RD1–D3 complex
with D1-D2 from the mCSF-1/mCSF-1RD1–D3 complex shows that D3 of the
IL-34 bound form (pale blue) rotates by 27 relative to the position of D3 of the
CSF-1 bound form (pale green).
(B) Close view of the hinge regions of the D2-D3 interfaces of the IL-34 bound
form (pale blue) and the CSF-1 bound form (pale green).
(C and D) Receptor-contacting residues mapped on to the secondary struc-
ture of IL-34 (C) and CSF-1 (D). The Site 1 and Site 2 interfacial residues
are shown in bright orange and olive, respectively, and highlighted by
dotted oval.
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Structures of Human IL-34 and IL-34/CSF-1R Complexby IL-34 triggers a rotation between D2 and D3 of CSF-1R,
producing an elongated, nearly linear pose that is significantly
different from the kinked configuration of the CSF-1 bound
form. The receptor-contacting residues, when mapped on to
the secondary structure of both cytokines, clearly show that
both interaction sites are more spread out on IL-34 than on
CSF-1 (Figures 6C and 6D). This is mainly due to the distinct
structural features outside the four-helix bundle core, namely,
a3 and a4. Hence, a flatter interface is created on IL-34, requiring
a more extended conformation of the receptor, while CSF-1
protrudes more into a cleft between CSF-1R D2 and D3 created
from their more ‘‘bent’’ orientation. The interface between neigh-
boring domains D2 and D3 is minimal in the CSF-1/receptor
complex, yet the only salt bridge between D3 E230 and D2
K194 in that complex is broken in the IL-34/receptor complex, al-
lowing D2 and D3 to adopt the almost linear arrangement upon
IL-34 binding (Figure 6B).
In contrast, the receptor D1-D2-D3 region of KIT appears to
behave as a rigid body upon SCF binding, where D4 and D5
realign and mediate receptor-receptor interactions between
the two SCF-bound KIT molecules (Yuzawa et al., 2007). In
KIT, there is a significant hydrophobic interface between
domains D2-D3, which is absent in CSF-1R. Interdomain flexi-684 Structure 20, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rightsbility has been used as an adaptive mechanism by which
multiple viral proteins utilize the same host cell receptor for entry.
Two structurally unrelated proteins, themeasles virus hemagglu-
tinin and adenovirus type 11/21 knobs, share the first two SCR
domains of CD46, the linker between which is quite structurally
adaptable (Cupelli et al., 2010; Persson et al., 2007; Santiago
et al., 2010). Moreover, perturbation of receptor domain orienta-
tions can lead to pronounced functional consequences, as
demonstrated by a 14 rotation in erythropoietin receptor in
complex with synthetic agonist and antagonist peptides (Livnah
et al., 1998). IL-34 was reported to induce a stronger but more
transient activation of CSF-1R and more rapidly downregulate
CSF-1R levels compared to CSF-1 (Chihara et al., 2010).
Possibly, this reorientation of CSF-1R receptor domains could
modulate its signaling potency in combination with the different
affinity for these two cytokines.
Equally Spaced CSF-1R D3-D4 Junctions in the
Cytokine/CSF-1R Signaling Complexes Prime D4, D5
for Degenerative Signaling
Receptor-mediated homotypic interactions have been proposed
to play an indispensable role in the activation of type III/V RTKs.
Such interactions have been either captured structurally in the
case of KIT D4 (Yuzawa et al., 2007) and VEGFR2 D7 (Yang
et al., 2010), or characterized biochemically in the case of
PDGFRb (Shim et al., 2010). The nature of these interactions is
a pair of reciprocal salt bridges in the EF loop between the two
receptor KIT D4 domains (D7 in VEGFR or D4 in PDGFR). Due
to the relatively high sequence identity between CSF-1R and
KIT, punctuated by this conserved ionic pair in CSF-1R D4,
similar receptor homotypic interactions probably also drive
CSF-1R dimerization in relaying the ligand-binding signal across
themembrane. Given that our biophysical analyses indicate a 2:2
stoichiometry of IL-34/CSF-1R complexes in solution, the 2:1
IL-34/CSF-1R complex observed in our crystal structure was
most likely influenced by crystal packing. Attempts to identify
a different crystal form, which might capture the 2:2 IL-34/CSF-
1R complex, failed to produce diffracting crystals. Thus, we
modeled what the expected full 2:2 ligand/receptor signaling
complex would look like by applying the 2-fold symmetry
between two IL-34 protomers to CSF-1R. When the absent
copy of CSF-1R is added to the unoccupied site on the IL-34
dimer, the distance (60 A˚) between the two C termini of CSF-1R
D3 in this 2:2 IL-34/CSF-1R model is very similar to that in
the 2:2 CSF-1/CSF-1R model (62 A˚), and to that in the 2:2
SCF/KIT structure (64 A˚) (Figure 7). Taken together, although
the hinge between CSF-1R D2-D3 can adopt very different
conformations to adapt to distinct surface topographies of the
two cytokines, the reorientation of D2-D3 nonetheless results in
the D3-D4 junction being spaced equivalently in the two cyto-
kine/receptor assemblies, presenting CSF-1R D4 as a conver-
gent point for homotypic interactions to elicit degenerative
responses downstream.
Ligand-Binding Cross-Reactivity by CSF-1R Utilizes
Distinct Mechanisms from Shared Hematopoietic
Cytokine Receptors
The molecular mechanisms of cytokine-binding cross-reactivity
have been deciphered for a number of shared cytokinereserved
Figure 7. Comparison of the Human IL-34/CSF-1R, Murine CSF-1/
CSF-1R, and SCF/KIT Signaling Complex Structures
Left, human IL-34/CSF-1R; middle, murine CSF-1/CSF-1R (PDB 3EJJ); and
right, SCF/KIT (PDB 2E9W) signaling complex structures. The dimeric four-
helix bundle cytokines are shown as cartoons and semitransparent surfaces.
Receptor ectodomains are rendered as ribbon representations or shown as
ovals for CSF-1R D4 and D5. The receptors are indicated using the following
scheme: D1 in pale yellow, D2 in bright orange, D3 in olive, D4 in lime, and D5 in
forest. The ionic pairs those have been implicated in the receptor homotypic
contacts of CSF-1R and KIT are shown as circles and annotated. The letter P
indicates trans-autophosphorylation of key tyrosine residues in the cyto-
plasmic domain.
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Structures of Human IL-34 and IL-34/CSF-1R Complexreceptors, such as the common gamma chain (gc), gp130, and
interferon a receptors (IFNAR1/2), since they all have been
captured structurally in at least two different ligand-bound states
(Thomas et al., 2011; Wang et al., 2009). Although the cytokine-
binding site is housed at the interdomain junction in both shared
class I cytokine receptors, no significant elbowmovements have
been observed by comparing the IL-2/gc quaternary complex
with IL-4/gc ternary complex (LaPorte et al., 2008; Wang et al.,
2005) or the unliganded gp130 with three gp130 family cytokine
complexes (Boulanger et al., 2003a, 2003b; Bravo et al., 1998;
Chow et al., 2001). gc and gp130 use ‘‘chemically inert comple-
mentary surfaces,’’ with a shared hydrophobic core region
surrounded by peripheral polar patches, to recognize short-
chain and long-chain cytokines, respectively (Boulanger et al.,
2003a; Wang et al., 2009). The recently determined type I IFN
receptor complexes revealed that paralogs IFNa2 and IFNu
are sandwiched between the first three FNIII domains of IFNAR1
(SD1-SD3) and the two FNIII-like domains of the more compact
IFNAR2 (D1, D2) (Thomas et al., 2011). Although the N-terminal
SD1 domain rotates relative to the SD2-SD3 segment of IFNAR1
upon IFN binding, once bound to the IFN, IFNAR1 exhibits nearly
identical conformations regardless of the identity of the bound
cytokine. Both IFNAR1 and IFNAR2 rely on a few conserved
‘‘anchor point’’ residues on the surface of type I IFNs for cross-
reactivity (Thomas et al., 2011).
By comparison, the structural basis of CSF-1R cross-reac-
tivity is quite different from the aforementioned shared cytokine
receptors. The core and peripheral binding interface architecture
on CSF-1R is somewhat similar to the class I cytokine/receptor
recognition paradigm, although CSF-1R uses mainly polar inter-
actions in Site 1 as its core, instead of hydrophobic interactions
as observed in gc and gp130. CSF-1R clearly relies to a greaterStructure 20extent on its conformational plasticity to enable cross-reactivity,
a structural adaptation not seen in other shared cytokine recep-
tors. This is perhaps not surprising, considering that IL-34 shares
merely 11% sequence identity with CSF-1 and has escaped the
recognition by predictive bioinformatics routines (Conklin et al.,
2005), although more sensitive fold recognition methods fare
better (J.F.B., unpublished data). CSF-1R manages to keep
impressive affinity toward IL-34 and CSF-1 during evolution by
a combination of interdomain structural plasticity and composi-
tional changes of interfacial residues. This provides a very effi-
cient (although not the only) mechanism, as witnessed in other
cytokine systems, of dual recognition of distantly related helical
cytokines.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The coding sequences of human IL-34 (residues N21–V193 for hIL-34s and
residues N21-P242 for hIL-34fl) fused with C-terminal Flag-tag or His6-tag,
and the extracellular domains of human CSF-1R (residues 20–299 for domains
D1–D3 and residues 20–512 for domains D1–D5) attached with C-terminal
His6-tag, were cloned into the pAcGP67 vector (BD Biosciences). Recombi-
nant baculovirus was generated by cotransecting sf9 cells with the pAcGP67A
construct and linearized baculovirus DNA in ESF 921 media (Expression
Systems) using the BaculoGold Expression System (PharMingen). Virus was
generated through three rounds of amplification and 4 ml of the round-3 stock
was used to infect 1 L of Tni.PRO cells at a density of 2 3 106 cells/ml. Cells
were grown 48 hr at 27C and removed from the media by centrifugation.
Supernatant was removed from cells and supplemented with 1 mM NiCl2,
5 mM CaCl2, in 50 mM Tris-HCl, pH 7.5. The protein in the supernatant was
captured by Ni-NTA column (QIAGEN) using gravity flow, washed with 30 ml
wash buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10 mM imidazole), and
eluted with elution buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 300 mM
imidazole). Protein was concentrated and further purified over a size exclusion
column (HiLoad 16/60 Superdex 200, GE Biosciences) equilibrated with 5 mM
Tris-HCl, pH 7.5, and 100 mM NaCl. Fractions containing proteins of interest
were analyzed by SDS-PAGE and pooled, and concentrations were deter-
mined by the absorbance at 280 nm.
Analytical SEC
Protein samples (500 ml) at 1 mg/ml concentration were injected sequentially
into a Superdex 200 10/300 GL column equilibrated with PBS. The same
column was calibrated by a mixture of protein molecular weight standards
(Bio-Rad), and the elution volumes of the proteins of interest were used to esti-
mate their corresponding molecular weight.
Isothermal Titration Calorimetry
All protein samples were buffer-exchanged into PBS using a Superdex 200
10/300 GL column prior to isothermal titration calorimetry (ITC) experiments
to minimize buffer dilution effects. Calorimetric titrations were carried out on
a VP-ITC 200 calorimeter (MicroCal), and the data were processed with Micro-
Cal Origin 7.0 software. The CSF-1RD1–D3 or CSF-1RD1-D5, the injectant, was
added to cells containing IL-34, CSF-1, or IL-34/CSF-1RD1–D3 complex over
the course of a number of injections until the cytokines were fully saturated.
Crystallization and Structure Determination
Complete data sets to 1.85 A˚, 3.0 A˚, 2.6 A˚ and 3.0 A˚ were collected from single
crystals of hIL-34s, hIL-34s/CSF-1RD1–D3 complex, hIL-34s/FAb2 complex,
and hIL-34s/FAb1.1 complex, respectively (Table 1). Full crystallographic
details are described in Supplemental Experimental Procedures.
Cell Viability and Proliferation Assay
Human peripheral blood mononuclear cells (PBMC) were isolated by gradient
centrifugation over Ficoll. A total of 1 3 104 freshly isolated PBMC per well in
96-well plates were stimulated with hIL-34fl, hIL-34s or CSF-1 in serial dilu-
tions. After incubation at 37C for 72 hr, ATP levels in cells were measured, 676–687, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 685
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Structures of Human IL-34 and IL-34/CSF-1R Complexwith the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega) for deter-
mining cell viability/proliferation. The response is shown as relative lumines-
cent units (RLUs).
Neutralization of Human IL-34 Bioactivity by IL-34 Antibodies
To measure the ability of full-length immunoglobulin G to neutralize the bioac-
tivity of hIL-34 on PBMC, we used a cell proliferation assay by CellTiter-Glo.
hIL-34 was combined with serial dilutions of anti-IL-34 or anti-CSF1 mAbs
(R&D Systems) before adding on to cells in a total volume of 100 ml. The anti-
body inhibition activity was obtained by measuring RLUs after incubating the
plates at 37C for 72 hr. The half maximal inhibitory concentration (IC50) is
defined as the concentration of antibody required to yield half maximal inhibi-
tion of IL-34 activity on cells when IL-34 is present at a concentration to elicit
70%–80% proliferation response.
Antibody Generation by Phage Display
Human phage antibody libraries with synthetic diversities in the selected CDRs
were used for panning. A rigorous description of antibody identification, affinity
maturation, and measurement are included in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the Protein Data
Bank with accession codes 4DKC, 4DKD, 4DKE, and 4DKF for hIL-34s, hIL-
34s/hCSF-1RD1–D3, hIL-34s/FAb1.1, and hIL-34s/FAb2, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.str.2012.02.010.
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